Canada - English - Health Canada

boehringer ingelheim (canada) ltd ltee - telmisartan; amlodipine (amlodipine besylate) - tablet - 80mg; 10mg - telmisartan 80mg; amlodipine (amlodipine besylate) 10mg - angiotensin ii receptor antagonists

United States - English - NLM (National Library of Medicine)

boehringer ingelheim - meperidine hydrochloride (unii: n8e7f7q170) (meperidine - unii:9e338qe28f) - solution - 50 mg in 5 ml - meperidine is indicated for the relief of moderate to severe pain. meperidine is contraindicated in patients with hypersensitivity to meperidine. meperidine is contraindicated in patients who are receiving monoamine oxidase (mao) inhibitors or those who have recently received such agents. therapeutic doses of meperidine have occasionally precipitated unpredictable, severe, and occasionally fatal reactions in patients who have received such agents within 14 days. the mechanism of these reactions is unclear, but may be related to a preexisting hyperphenylalaninemia. some have been characterized by coma, severe respiratory depression, cyanosis, and hypotension, and have resembled the syndrome of acute narcotic overdose. in other reactions the predominant manifestations have been hyperexcitability, convulsions, tachycardia, hyperpyrexia, and hypertension. although it is not known that other narcotics are free of the risk of such reactions, virtually all of the reported reactions have occurred with meperidine. if

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 25 mg - tablet, multilayer - excipient ingredients: maize starch; sorbitol; sodium hydroxide; iron oxide yellow; magnesium stearate; lactose monohydrate; microcrystalline cellulose; povidone; sodium starch glycollate type a; meglumine - micardis plus is indicated for the treatment of hypertension. treatment should not be intitiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sodium hydroxide; sorbitol; microcrystalline cellulose; iron oxide red; maize starch; lactose monohydrate; povidone; sodium starch glycollate - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - hydrochlorothiazide, quantity: 12.5 mg; telmisartan, quantity: 40 mg - tablet, multilayer - excipient ingredients: povidone; sodium hydroxide; microcrystalline cellulose; lactose monohydrate; sorbitol; sodium starch glycollate; maize starch; meglumine; magnesium stearate; iron oxide red - micardis plus is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; sodium hydroxide; sorbitol; meglumine - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sorbitol; sodium hydroxide; povidone; meglumine; magnesium stearate - micardis is indicated for:,?treatment of hypertension in adults,?prevention of cardiovascular morbidity and mortality in adults 55 years or older withcoronary artery disease, peripheral artery disease, previous stroke, transient ischaemicattack or high risk diabetes with evidence of end organ damage (see section 5.1pharmacodynamic properties, clinical trials)

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

boehringer ingelheim animal health australia pty. ltd. - selenium as sodium selenite; cyanocobalamin (vitamin b12) - parenteral liquid/solution/suspension - selenium as sodium selenite mineral-selenium active 3.3 g/l; cyanocobalamin (vitamin b12) vitamin-b12 active 1.4 g/l - nutrition & metabolism

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - olodaterol hydrochloride, quantity: 2.736 microgram/actuation (equivalent: olodaterol, qty 2.5 microgram/actuation); tiotropium bromide monohydrate, quantity: 3.124 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; benzalkonium chloride; hydrochloric acid; disodium edetate - yanimo respimat is indicated as a once-daily maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Australia - English - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - tiotropium bromide monohydrate, quantity: 3.1235 microgram/actuation (equivalent: tiotropium, qty 2.5 microgram/actuation) - inhalation, conventional - excipient ingredients: purified water; hydrochloric acid; disodium edetate; benzalkonium chloride - copd: srivasso respimat is indicated for the long term maintenance treatment of bronchospasm and dyspnoea associated with chronic obstructive pulmonary disease (copd). srivasso respimat is indicated for the prevention of copd exacerbations.,asthma: srivasso respimat is indicated as add-on maintenance bronchodilator treatment in patients aged 6 years and older with moderate to severe asthma.